Addition of rituximab to chemotherapy reduced the rate of surgery for gastric-DLBCL without increasing early mortality

Academic Article

Abstract

  • Background: We evaluated surgical trends for gastric diffuse large B-cell lymphoma (gDLBCL) before and after the approval of rituximab and whether an association of early mortality existed in patients treated after approval of rituximab. Patients and Methods: We utilized the Surveillance Epidemiology and End Results (SEER) 18 database to extract data on patients with gDLBCL diagnosed between 1983-2012. Primary site-specific cancer-directed surgery using SEER sitespecific surgical codes and annual trends were analyzed. Patients were analyzed before and after 2006, the year rituximab gained U.S. Food and Drug Administration approval. Results: Joinpoint trend analysis showed the sharpest decline in surgical rates between 2000-2010. Adjusted surgical rates computed using poisson regression declined from 54.4% in 1983 to 6.9% in 2012, with an annual percentage change of-8.9% (95% confidence interval=-9.7% to-8.3%; p-value <0.01). No significant mortality increase at 30 and 60 days was found. Conclusion: While rituximab appears to have significantly changed how surgery is utilized for patients with gDLBCL, early mortality was unchanged.
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Prouet P; Giri S; Wiedower E; Fintel A; Yaghmour G; Lamb EP; Deneve J; Fleming M; Dickson P; Chandler JC
  • Start Page

  • 813
  • End Page

  • 818
  • Volume

  • 37
  • Issue

  • 2